New drug duo aims to tackle Hard-to-Treat cancers
NCT ID NCT07602855
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a first step to see if this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Risvutatug rezetecan (Ris-Rez) and ivonescimab
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid cancers that have stopped responding to other therapies.
- What could go wrong
- This is a very early (phase 1/2) study with only 184 participants, so it's too soon to know if the combination is truly effective or safe. Side effects are unknown and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo outperform standard therapy for lung cancer?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a novel drug combo outperform chemo in lung cancer?